ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)
Effects of Glucagon-Like Peptide-1 Analogs on Sexual Desire: A randomized, double-blind, placebo-controlled crossover trial
Sophia Lengsfeld 1 , Flavia Hasenböhler 1 , Leila Probst 1 , Fabienne Baur 1 , Yara Emara 1 , Cemile Bathelt 1 , Laura Werlen 1,2 , Deborah Vogt 1,2 , Brida Caviezel 1 , Tanja Vukajlovic 1 , Mirjam Christ-Crain 1 & Bettina Winzeler 1
1University Hospital Basel, Endocrinology, Diabetology and Metabolism, Basel, Switzerland; 2University Hospital Basel, Departement of Clinical Research, Basel, Switzerland
Background: GLP-1 analogs are prescribed for diabetes and obesity due to their well-known insulinotropic, satiation-promoting and appetite-suppressant effects. Several studies also investigated the effects of GLP-1 analogs on reward to addictive drugs such as alcohol, nicotine and cocaine. Pre-clinical studies suggest that sexual desire, as another type of natural reward, could also be affected by GLP-1 analogs. Since sexuality is a very important aspect of human wellbeing and the use of GLP-1-analogs is becoming more frequent in a broad spectrum of diabetic and obese patients in all age groups, the aim of this study was to investigate the influence of GLP-1-analogs on sexual desire and sex hormones.
Methods: This was a single-center, randomized, double-blind, placebo-controlled, crossover trial conducted at the University Hospital Basel in Switzerland. We enrolled healthy eugonad men of normal weight (BMI 18.5-25kg/m2 or BMI 25.1-30kg/m2 and waist circumference <102 cm), aged between 18 and 50 years who reported an active and satisfactory sex life. Participants were randomized to dulaglutide and placebo in random order. In the primary analysis, we tested the difference in change in sexual desire, assessed via the Massachusetts General Hospital - Sexual Functioning Questionnaire (MGH-SFQ), after four weeks of treatment with dulaglutide compared to placebo using a paired t-test. In secondary analyses, we examined the effect of four weeks of treatment with dulaglutide as compared to placebo on hormones of the reproductive axis (total testosterone, FSH, LH) using paired t-tests and adjusted for multiple comparisons using the Bonferroni-Holm procedure.
Results: Between May 2021 and February 2022, 24 out of 26 randomized participants completed the study. The average MGH-SFQ change from baseline after 4 weeks of dulaglutide was 1.0 (SD 2.2) and 0.4 (SD 2.7) under placebo (estimated difference in change of the MGH-SFQ sum score from baseline to end of treatment under dulaglutide and under placebo 0.6 (95% CI: [-0.8-2.0], P-value = 0.402). Analyzed hormones of the gonad axis did not show statistically significant differences.
Conclusion: In healthy men, dulaglutide had no clinically relevant effect on sexual desire nor on analyzed hormones of the gonad axis.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more